Last reviewed · How we verify
oxytocin 5 u
oxytocin 5 u is a Small molecule drug developed by Oslo University Hospital. It is currently FDA-approved. Also known as: Syntocinon, injection.
Oxytocin is a small molecule used in medical research, specifically studied in the context of its effects on anesthesia, pregnancy, and cardiac output. It has been investigated as an intervention in clinical trials, including those examining its use after cesarean section under spinal anesthesia.
At a glance
| Generic name | oxytocin 5 u |
|---|---|
| Also known as | Syntocinon, injection |
| Sponsor | Oslo University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Changes in Cardiac Output During Cesarean Delivery Under Spinal Anesthesia
- Carbetocin Versus Oxytocin and Hemodynamic Effects (PHASE4)
- Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxytocin 5 u CI brief — competitive landscape report
- oxytocin 5 u updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI
Frequently asked questions about oxytocin 5 u
What is oxytocin 5 u?
Who makes oxytocin 5 u?
Is oxytocin 5 u also known as anything else?
What development phase is oxytocin 5 u in?
Related
- Manufacturer: Oslo University Hospital — full pipeline
- Also known as: Syntocinon, injection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing